

Clinical Policy Advisory Group (CPAG)

CLINICAL & GOVERNACE POLICIES UPDATED EVIDENCE BASED INTERVENTIONS AND LOCAL POLICIES

Research evidence shows that some interventions are not clinically effective or only effective when they are performed in specific circumstances. The purpose of the Evidence Based Interventions (EBI) policy is to clarify the commissioning intentions of the Integrated Care Board (ICB). The ICB will only fund treatment for clinically effective interventions that are then delivered to the appropriate cohort of patients. When updating Clinical Policies CPAG undertakes Stakeholder engagement with Specialists/Consultants/Clinicians.

There were no local clinical or governance policies approved and ratified this month.

	MISCELLANEOUS INFORMATION				
Statement	Summ	2			
Hip Arthroscopy Position Statement - Evidence Review	The position statement remains unchanged, NHS Derby & Derbyshire ICB will not routinely commission hip arthroscopy surgery. Following the ratification of the Hip Arthroscopy Position Statement in November 2023. CPAG were asked to				
	consider additional evidence on the impact of arthroscopy, for young adult hip patients with femoracetabu impingement.				
	Upon evaluation, there has been no new substantial robust evidence that has been published since th position statement was last reviewed in November 2023 that would support a change in the position statement commissioning stance. In line with CPAG operating process new evidence will be considered at the new scheduled position statement review date in October 2026.				
Glossop Transition for Clinical Policies Update	A decision was taken by the Government in July 2021 to amend the Derbyshire Integrated Care System (ICS boundary to align Glossop within the Derbyshire ICS from the Greater Manchester ICS.				
	 For existing clinical policies, the Clinical Policies department have agreed to follow a framework agreed with the Engagement Team at DDICB. The work programme is managed via an internal ICB Glossop Transition Group meeting which is usually held on a monthly basis. Due to reduced capacity within the Clinical Policies Team including the loss of the Policy writer, a temporary measure has been put in place to extend the review period for policies due for review in the next 6 months for a further 12 months. CPAG are assured the existing policy is safe and no new significant evidence has been published since the policy was last reviewed. The Clinical Policies and Decisions Team have engaged with the Medical Director at Derby and Derbyshire Local Medical Committee (LMC) and a Glossop clinical representative to review the extended policies to assess variation (please see table below). As agreed with DDICB Engagement Team, the Public Patient Involvement (PPI) process will not be required where the following apply: Policies where DDICB and Greater Manchester are aligned 				
	 Greater Manchester do not have an existing policy There is National guidance e.g. Evidence Based Interventions (EBI) programme Broadly aligned with very minor differences 				
	<u>Speciality</u>	DDICB policies – review dates extended by 12 months			
	Not Routinely Commissioned - Cosmetic Procedures	Cranial banding			
		Resurfacing by laser for skin conditions causing scarring – including post-acne and post traumatic scarring			
		Hair transplantation			
		Hair Depilation (Removal) for Excessive Hair Growth (Hirsutism)			
		Excess skin removal on thigh, leg, hip, buttock, forearm or other area (with the exception of Apronectomy where criteria are met)			
		Phalloplasty			

	Labiaplasty, Vaginoplasty and hymen reconstruction			
	Botulinum Toxin - When Used to Improve Cosmetic Appearance			
	Laser treatment for facial hyperpigmentation			
Commissioned with Restrictions - Cosmetic Procedures	Earlobe repair			
	Cheek implants			
	Chin implants			
	Collagen implant			
	Fat grafts			
	Nipple inversion			
	Face lifts			
	Lipectomy/Liposuction			
	Breast Asymmetry Surgery Policy			
	Surgical Removal of Epidermoid and Pilar Cysts Policy			
	Surgical Removal of Lipoma/Lipomata Policy			
	Laser Treatment Policy for Skin Conditions			
	Laser Treatment Policy for Skin Conditions Treatment of Congenital Pigmented Lesions on the Face Policy			
Cardiology - not routinely commissioned	Laser Treatment Policy for Skin Conditions Treatment of Congenital Pigmented Lesions on the Face Policy Exercise ECG for Coronary Heart Disease (Position Statement)			
Ear Nose & Throat (ENT) - commissioned with restrictions	Laser Treatment Policy for Skin Conditions Treatment of Congenital Pigmented Lesions on the Face Policy Exercise ECG for Coronary Heart Disease (Position Statement) Surgical Intervention for Chronic Rhinosinusitis Policy			
Ear Nose & Throat (ENT) - commissioned with	Laser Treatment Policy for Skin Conditions Treatment of Congenital Pigmented Lesions on the Face Policy Exercise ECG for Coronary Heart Disease (Position Statement) Surgical Intervention for Chronic Rhinosinusitis Policy Dilatation and Curettage (D&C) for Heavy Menstrual Bleeding in Women Policy			
Ear Nose & Throat (ENT) - commissioned with restrictions Gynaecology & Fertility - not routinely commissioned	Laser Treatment Policy for Skin Conditions Treatment of Congenital Pigmented Lesions on the Face Policy Exercise ECG for Coronary Heart Disease (Position Statement). Surgical Intervention for Chronic Rhinosinusitis Policy Dilatation and Curettage (D&C) for Heavy Menstrual Bleeding in Women Policy Reversal of Male and Female Sterilisation (Position Statement).			
Ear Nose & Throat (ENT) - commissioned with restrictions	Laser Treatment Policy for Skin Conditions Treatment of Congenital Pigmented Lesions on the Face Policy Exercise ECG for Coronary Heart Disease (Position Statement) Surgical Intervention for Chronic Rhinosinusitis Policy Dilatation and Curettage (D&C) for Heavy Menstrual Bleeding in Women Policy Reversal of Male and Female Sterilisation (Position Statement) Hysterectomy for Menorrhagia Policy			
Ear Nose & Throat (ENT) - commissioned with restrictions Gynaecology & Fertility - not routinely commissioned Gynaecology & Fertility - commissioned with restrictions	Laser Treatment Policy for Skin Conditions Treatment of Congenital Pigmented Lesions on the Face Policy Exercise ECG for Coronary Heart Disease (Position Statement) Surgical Intervention for Chronic Rhinosinusitis Policy Dilatation and Curettage (D&C) for Heavy Menstrual Bleeding in Women Policy Reversal of Male and Female Sterilisation (Position Statement) Hysterectomy for Menorrhagia Policy Fitting/Removal of Intra-Uterine Contraceptive Devices and Levonorgestrel Intrauterine Systems in Secondary Care Policy			
Ear Nose & Throat (ENT) - commissioned with restrictions Gynaecology & Fertility - not routinely commissioned Gynaecology & Fertility - commissioned with restrictions	Laser Treatment Policy for Skin Conditions Treatment of Congenital Pigmented Lesions on the Face Policy Exercise ECG for Coronary Heart Disease (Position Statement) Surgical Intervention for Chronic Rhinosinusitis Policy Dilatation and Curettage (D&C) for Heavy Menstrual Bleeding in Women Policy Reversal of Male and Female Sterilisation (Position Statement). Hysterectomy for Menorrhagia Policy Fitting/Removal of Intra-Uterine Contraceptive Devices and Levonorgestrel Intrauterine Systems in Secondary Care Policy Acupuncture (Position Statement)			
Ear Nose & Throat (ENT) - commissioned with restrictions Gynaecology & Fertility - not routinely commissioned Gynaecology & Fertility - commissioned with restrictions Miscellaneous - not routinely commissioned Neurology - commissioned with restrictions	Laser Treatment Policy for Skin Conditions Treatment of Congenital Pigmented Lesions on the Face Policy Exercise ECG for Coronary Heart Disease (Position Statement) Surgical Intervention for Chronic Rhinosinusitis Policy Dilatation and Curettage (D&C) for Heavy Menstrual Bleeding in Women Policy Reversal of Male and Female Sterilisation (Position Statement) Hysterectomy for Menorrhagia Policy Fitting/Removal of Intra-Uterine Contraceptive Devices and Levonorgestrel Intrauterine Systems in Secondary Care Policy Acupuncture (Position Statement) Lycra body suits for postural management of cerebral palsy and other musculoskeletal/ neurological conditions Policy			
Ear Nose & Throat (ENT) - commissioned with restrictions Gynaecology & Fertility - not routinely commissioned Gynaecology & Fertility - commissioned with restrictions	Laser Treatment Policy for Skin Conditions Treatment of Congenital Pigmented Lesions on the Face Policy Exercise ECG for Coronary Heart Disease (Position Statement) Surgical Intervention for Chronic Rhinosinusitis Policy Dilatation and Curettage (D&C) for Heavy Menstrual Bleeding in Women Policy Reversal of Male and Female Sterilisation (Position Statement) Hysterectomy for Menorrhagia Policy Fitting/Removal of Intra-Uterine Contraceptive Devices and Levonorgestrel Intrauterine Systems in Secondary Care Policy Acupuncture (Position Statement) Lycra body suits for postural management of cerebral palsy and other musculoskeletal/			

	Ophthalmology - commissioned wit	logy - commissioned with restrictions Cataract Surgery Policy		ery Policy		
	Orthopaedics - not routinely comm	issioned	Arthroscopic S Tears (Position	urgery for Degenerate Meniscal		
	Orthopaedics - commissioned with restrictions		Lumbar Radiofrequency Facet Joint Denervation Policy			
			Spinal Decomp	pression for Sciatica Policy		
	Outcome of the Public Patient Involvement (PPI) process where variation identified. The outcomes of the PPI Assessment process for the following clinical policies/position statements are:					
	DDICB policies – review dates extended by 12 months	S Variation Identified		Outcome of PPI process		
	Cataract Surgery Policy	Second eye criteria		Acceptance of policy variation from lead commissioner		
	Breast Asymmetry Surgery Policy Oraya Therapy Position Statement	BMI & measureme No specific policy i However, recogniti difference with Sh	dentified. on of border	Inform (via the CPAG bulletin) Inform (via the CPAG bulletin)		
Close down of Prior Approvals - EBI (formerly PLCV) and Cosmetics Referral Assessment Service	Following the publication of the new Derby & Derbyshire Integrated Care Board (DDICB) organisatio structures, it has been confirmed that the Prior Approval services for Evidence Based Interventions (E (formally Procedures of Limited Clinical Value) and Cosmetics Referral Assessment Service will no longer be necessary function of DDICB. This is a legacy assurance function which reflects historic contracting arrangements and is now consider embedded practice linked to clinical policies and contract standards. As referral management is a collaborat between providers, the cessation of this function does not impact patient care pathways.					
	Derbyshire providers continue to be engaged in the ongoing review, development and implementation of clinical policies.					
	The changes to the process for referral are outlined below:					
	 Primary care referrals There is no longer a requirement for the clinician to obtain "Prior Approval" from the DDICB Service before referring a patient into secondary care. Referrals are to be sent directly to the appropriate service on the NHS e-Referral Service. Secondary care These treatments will no longer require Prior Approval (Blueteq). It will remain the responsibility of the clinicians involved in the patient's care to check the policy criteria and the patient's eligibility for treatment. The above arrangement plans were operationalised on <u>Monday 18th March 2024</u>. The service is no longer available on the e-Referral Service and Prior Approval forms have been disabled on the Blueteq system. A letter of communication and FAQ which covers salient points can be accessed on the Derbyshire Medicines Management and Clinical Policies website using the following link: https://www.derbyshiremedicinesmanagement.nhs.uk/clinical-policies-home 					
	A close down report has been compl	eted, which was note	ed by CPAG.			
<u>Review Date</u> <u>Extension of CPAG</u> Terms of Reference	Due to the ICB re-structure and a pause in recruitment across the ICB, CPAG agreed to extend the review date for the CPAG Terms of Reference (ToR) for a further 6 months.					
	The following minor amendment has been made to the CPAG Terms of Reference to reflect structure:					
Individual Funding Requests (IFR) Terms of Reference Review Date	CPAG agreed to extend the review timescale to 3 years, to align to the review date of the IFR P					
	The IFR Terms of Reference include IFR Screening Pair IFR Panel 	the following panels	:			
Individual Funding Requests (IFR) Screening Cases	IFR Review Panel	g cases for Februar	ry 2024 and are	e assured that no areas for service		

NICE INTERVENTIONS, DIAGNOSTICS, MEDICAL AND HEALTH TECHNOLOGIES AND INNOVATION PROGRAMMES The DDICB does not commission and will not fund any procedure or technology assessed by NICE under their IPG, MTG, DTG, MIB or HTE programmes unless: • the provider has submitted a robust, evidenced based business case to the commissioner and this has been subsequently approved AND

- the NICE IPG states 'use with standard arrangements for clinical governance, consent and audit'
- OR the NICE MTG states 'the case for adoption within the NHS as described is supported by the evidence'
- OR the NICE DTG makes a recommendation as an option for use
- OR the NICE MIB has evaluated the innovation
- OR the NICE HTE has made a recommendation for use while evidence is being generated

The following NICE programme outputs were noted by the group for the month of February 2024:

IPG/MTG/DTG/HTE/MIB	Description	Outcome
IPG783	Endoscopic sleeve gastroplasty for obesity	NICE recommends standard
		arrangements – not
		commissioned without the
		provider submitting a robust,
		evidenced based business
		case to the commissioner
		and subsequent approval
HTE8 (update)	Digitally enabled therapies for adults with depression: early value assessment	NICE does not recommend –
		company no longer trading,
	Update Information:	DDICB do not commission
	February 2024: The technology Beating the Blues has been removed from	
	recommendation <u>1.1</u> because it is no longer available to the NHS. This is	
	because the company for the technology, 365 Health Solutions, is no longer	
	trading.	

Our ICB continues to monitor and implement IPGs with our main providers.